WO2001095919A3 - A recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses - Google Patents
A recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses Download PDFInfo
- Publication number
- WO2001095919A3 WO2001095919A3 PCT/US2001/019201 US0119201W WO0195919A3 WO 2001095919 A3 WO2001095919 A3 WO 2001095919A3 US 0119201 W US0119201 W US 0119201W WO 0195919 A3 WO0195919 A3 WO 0195919A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- csf
- antigen
- encoding
- replication
- enhancing
- Prior art date
Links
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 title abstract 7
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 title abstract 7
- 230000028993 immune response Effects 0.000 title abstract 4
- 241000700605 Viruses Species 0.000 title abstract 3
- 230000003362 replicative effect Effects 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 5
- 102000036639 antigens Human genes 0.000 abstract 5
- 108091007433 antigens Proteins 0.000 abstract 5
- 230000002708 enhancing effect Effects 0.000 abstract 4
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 3
- 230000003053 immunization Effects 0.000 abstract 2
- 238000002649 immunization Methods 0.000 abstract 2
- 241000271566 Aves Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 230000003308 immunostimulating effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000004235 neutropenia Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000004044 response Effects 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/001139—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46448—Cancer antigens from embryonic or fetal origin
- A61K39/464482—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/50—Colon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU6845201A AU6845201A (en) | 2000-06-15 | 2001-06-15 | A recombinant non-replicating virus expressing GM-CSF and uses thereof to enhance immune responses |
US10/297,168 US20040091995A1 (en) | 2001-06-15 | 2001-06-15 | Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses |
AU2001268452A AU2001268452B2 (en) | 2000-06-15 | 2001-06-15 | A recombinant non-replicating virus expressing GM-CSF and uses thereof to enhance immune responses |
CA2412050A CA2412050C (en) | 2000-06-15 | 2001-06-15 | A recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses |
EP01946395A EP1292694A2 (en) | 2000-06-15 | 2001-06-15 | A recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses |
JP2002510097A JP2004507231A (en) | 2000-06-15 | 2001-06-15 | Recombinant non-replicating virus expressing GM-CSF and use thereof for enhancing an immune response |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21171700P | 2000-06-15 | 2000-06-15 | |
US60/211,717 | 2000-06-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001095919A2 WO2001095919A2 (en) | 2001-12-20 |
WO2001095919A3 true WO2001095919A3 (en) | 2002-11-28 |
Family
ID=22788060
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/019201 WO2001095919A2 (en) | 2000-06-15 | 2001-06-15 | A recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1292694A2 (en) |
JP (1) | JP2004507231A (en) |
AU (2) | AU6845201A (en) |
CA (1) | CA2412050C (en) |
WO (1) | WO2001095919A2 (en) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPQ755300A0 (en) | 2000-05-17 | 2000-06-08 | Monash University | Immune potentiating compositions |
US7628980B2 (en) | 2000-11-23 | 2009-12-08 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
US6684646B2 (en) | 2001-05-22 | 2004-02-03 | Integrated Biosystems, Inc. | Systems and methods for freezing, storing and thawing biopharmaceutical material |
SG173216A1 (en) * | 2002-04-19 | 2011-08-29 | Bavarian Nordic As | Modified vaccinia virus ankara for the vaccination of neonates |
AU2003900767A0 (en) * | 2003-02-21 | 2003-03-13 | St Vincent's Hospital Sydney Limited | Idiotypic vaccine |
BRPI0413334A (en) * | 2003-09-05 | 2006-10-10 | Sanofi Pasteur Ltd | multigene vectors for melanoma |
WO2005047483A2 (en) | 2003-11-12 | 2005-05-26 | Medical Research Council | Renta: an hiv immunogen and uses thereof |
NZ552745A (en) * | 2004-07-16 | 2009-01-31 | Micromet Ag | Expression-enhanced polypeptides |
ES2396915T3 (en) | 2006-06-02 | 2013-03-01 | International Aids Vaccine Initiative | Consensus sequences, antigens and transgenes of HIV-1 of clade A |
EP2349296B1 (en) * | 2008-08-21 | 2017-04-05 | Ottawa Hospital Research Institute | Engineered synergistic oncolytic viral symbiosis |
CA2742049A1 (en) * | 2008-10-31 | 2010-05-06 | The Brigham And Women's Hospital, Inc. | Vaccination with poxvirus vectors via mechanical epidermal disruption |
US8691502B2 (en) | 2008-10-31 | 2014-04-08 | Tremrx, Inc. | T-cell vaccination with viral vectors via mechanical epidermal disruption |
WO2012149038A1 (en) | 2011-04-25 | 2012-11-01 | Advanced Bioscience Laboratories, Inc. | Truncated hiv envelope proteins (env), methods and compositions related thereto |
CA2832109C (en) | 2011-06-10 | 2021-07-06 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
EP2586461A1 (en) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Viral particles derived from an enveloped virus |
WO2013093629A2 (en) | 2011-12-20 | 2013-06-27 | Netherlands Cancer Institute | Modular vaccines, methods and compositions related thereto |
US9347065B2 (en) | 2012-03-29 | 2016-05-24 | International Aids Vaccine Initiative | Methods to improve vector expression and genetic stability |
ES2631608T3 (en) | 2012-06-27 | 2017-09-01 | International Aids Vaccine Initiative | Env-glycoprotein variant of HIV-1 |
ES2807173T3 (en) | 2012-09-10 | 2021-02-22 | Int Aids Vaccine Initiative | Broadly Neutralizing HIV-1 Antibody Immunogens, Generation Methods, and Uses |
US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
EP2873423B1 (en) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
AU2014347004B2 (en) * | 2013-11-05 | 2019-08-08 | Bavarian Nordic A/S | Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and an antagonist and/or agonist of an immune checkpoint inhibitor |
WO2015171975A1 (en) | 2014-05-09 | 2015-11-12 | The Regents Of The University Of Michigan | Use of modified banana lectin in purification of glycoproteins |
US10093720B2 (en) | 2014-06-11 | 2018-10-09 | International Aids Vaccine Initiative | Broadly neutralizing antibody and uses thereof |
JP5917626B2 (en) * | 2014-07-28 | 2016-05-18 | トレムアールエックス, インコーポレイテッド | Vaccination with poxvirus vectors via mechanical epidermal destruction |
EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
US9925258B2 (en) | 2015-10-02 | 2018-03-27 | International Aids Vaccine Initiative | Replication-competent VSV-HIV Env vaccines |
TWI733719B (en) * | 2015-12-07 | 2021-07-21 | 美商河谷控股Ip有限責任公司 | Improved compositions and methods for viral delivery of neoepitopes and uses thereof |
CN108567977B (en) | 2017-03-13 | 2022-04-12 | 复旦大学 | Immunopotentiator, immunotherapy pharmaceutical composition, preparation and application thereof |
EP4106809A1 (en) | 2020-02-21 | 2022-12-28 | International AIDS Vaccine Initiative, Inc. | Vaccine compositions for preventing coronavirus disease |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994016716A1 (en) * | 1993-01-21 | 1994-08-04 | Virogenetics Corporation | Recombinant virus immunotherapy |
WO1996011279A2 (en) * | 1994-10-03 | 1996-04-18 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system |
WO1998015635A2 (en) * | 1996-10-04 | 1998-04-16 | Connaught Laboratories Limited | Treatment of cancer using a recombinant poxvirus containing a nucleic acid sequence encoding a cytokine |
-
2001
- 2001-06-15 AU AU6845201A patent/AU6845201A/en active Pending
- 2001-06-15 EP EP01946395A patent/EP1292694A2/en not_active Ceased
- 2001-06-15 AU AU2001268452A patent/AU2001268452B2/en not_active Expired
- 2001-06-15 JP JP2002510097A patent/JP2004507231A/en active Pending
- 2001-06-15 CA CA2412050A patent/CA2412050C/en not_active Expired - Lifetime
- 2001-06-15 WO PCT/US2001/019201 patent/WO2001095919A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994016716A1 (en) * | 1993-01-21 | 1994-08-04 | Virogenetics Corporation | Recombinant virus immunotherapy |
WO1996011279A2 (en) * | 1994-10-03 | 1996-04-18 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system |
WO1998015635A2 (en) * | 1996-10-04 | 1998-04-16 | Connaught Laboratories Limited | Treatment of cancer using a recombinant poxvirus containing a nucleic acid sequence encoding a cytokine |
Non-Patent Citations (7)
Title |
---|
GROSENBACH DOUGLAS W ET AL: "Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects.", CANCER RESEARCH, vol. 61, no. 11, 1 June 2001 (2001-06-01), pages 4497 - 4505, XP002189175, ISSN: 0008-5472 * |
GROSENBACH DOUGLAS WILLIAM ET AL: "Synergy of vaccine strategies to optimize antigen-specific immune responses and anti-tumor effects.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 42, March 2001 (2001-03-01), 92nd Annual Meeting of the American Association for Cancer Research;New Orleans, LA, USA; March 24-28, 2001, March, 2001, pages 818, XP002189174, ISSN: 0197-016X * |
HODGE JAMES W ET AL: "Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses.", VACCINE, vol. 15, no. 6-7, 1997, pages 759 - 768, XP002189173, ISSN: 0264-410X * |
KASS ERIK ET AL: "Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant.", CANCER RESEARCH, vol. 61, no. 1, 1 January 2001 (2001-01-01), pages 206 - 214, XP002189176, ISSN: 0008-5472 * |
PUISIEUX I ET AL: "CURATIVE AND PROTECTIVE EFFECTS AGAINST MURINE TUMORS BY IL12 GENE THERAPY USING A CANARYPOX VIRUS VECTOR", CANCER GENE THERAPY, NORWALK, CT, US, vol. 4, no. 6, 20 November 1997 (1997-11-20), pages S53, XP002062564, ISSN: 0929-1903 * |
PUISIEUX ISABELLE ET AL: "Canarypox virus-mediated interleukin 12 gene transfer into murine mammary adenocarcinoma induces tumor suppression and long-term antitumoral immunity.", HUMAN GENE THERAPY, vol. 9, no. 17, 20 November 1998 (1998-11-20), pages 2481 - 2492, XP002205540, ISSN: 1043-0342 * |
RAO G S ET AL: "CANARY-FOX (ALVAC) VIRUS-MEDIATED CYTOKINE GENE THERAPY INDUCES TUMOR SPECIFIC IMMUNITY AGAINST MOUSE BLADDER TUMOR", JOURNAL OF UROLOGY, BALTIMORE, MD, US, vol. 155, no. 5, 1 May 1996 (1996-05-01), pages 570A, XP002062560, ISSN: 0022-5347 * |
Also Published As
Publication number | Publication date |
---|---|
EP1292694A2 (en) | 2003-03-19 |
WO2001095919A2 (en) | 2001-12-20 |
AU6845201A (en) | 2001-12-24 |
JP2004507231A (en) | 2004-03-11 |
CA2412050C (en) | 2011-03-22 |
CA2412050A1 (en) | 2001-12-20 |
AU2001268452B2 (en) | 2006-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001095919A3 (en) | A recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses | |
US5747024A (en) | Vaccine adjuvant comprising interleukin-15 | |
WO2003011223A3 (en) | Immunomodulatory compounds and methods of use thereof | |
DK1800692T3 (en) | Immunological compositions and vaccines containing N-formyl-methionyl peptide as adjuvant | |
CA2293692A1 (en) | Methods and reagents for vaccination which generate a cd8 t cell immune response | |
WO2003024480A3 (en) | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles | |
HK1074578A1 (en) | Packaged virus-like particles in combination with cpg for use as adjuvants with allergens: method of preparation and use | |
CA2408328A1 (en) | Immunogenic polypeptides encoded by mage minigenes and uses thereof | |
WO2001039803A3 (en) | Interleukin-1 muteins useful as vaccine adjuvants | |
MXPA01007760A (en) | Immunological adjuvant compound. | |
WO2007149518A3 (en) | Dna composition against tumor stromal antigen fap and methods of use thereof | |
HUP0401355A2 (en) | Immunotherapeutic combinations for the treatment of tumours that overexpress gangliosides | |
WO2002034119A3 (en) | Vaccine immunotherapy for immune suppressed patients | |
CA2272338A1 (en) | Immunization of infants | |
AU1800597A (en) | Novel methods of vaccination and vaccines therefore comprising a nucleic acid encoding a first epitope and a peptide containing a second epitope | |
WO2004002408B1 (en) | Cancer vaccine containing cross-species epitopes of telomerase reverse transcriptase | |
EP1810691A3 (en) | Immunotherapy for reversing immune suppression | |
WO2001097841A3 (en) | Qs-21 and il-12 as an adjuvant combination | |
WO2003080111A3 (en) | Chemotherapeutic agents as anti-cancer vaccine adjuvants and therapeutic methods thereof | |
JP2002534481A5 (en) | ||
CA2360382A1 (en) | Use of antibodies for the vaccination against cancer | |
WO2004037175A3 (en) | Compositions and methods for treating human papillomavirus-mediated disease | |
RU2007112117A (en) | Vaccine Composition Against Hepatitis C Virus | |
NZ515322A (en) | Adjuvant combination formulations | |
WO2000006198A3 (en) | Adjuvant comprising pulmonary surfactant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001946395 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2412050 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001268452 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2002 510097 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 2001946395 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10297168 Country of ref document: US |